- Home
- HCC vs VKTX Comparison
HCC vs VKTX Comparison
Compare HCC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- VKTX
- Stock Information
- Founded
- HCC 2015
- VKTX 2012
- Country
- HCC United States
- VKTX United States
- Employees
- HCC N/A
- VKTX N/A
- Industry
- HCC Coal Mining
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- VKTX Health Care
- Exchange
- HCC Nasdaq
- VKTX Nasdaq
- Market Cap
- HCC 3.3B
- VKTX 3.8B
- IPO Year
- HCC 2017
- VKTX 2015
- Fundamental
- Price
- HCC $64.26
- VKTX $34.37
- Analyst Decision
- HCC Buy
- VKTX Strong Buy
- Analyst Count
- HCC 7
- VKTX 13
- Target Price
- HCC $71.17
- VKTX $85.54
- AVG Volume (30 Days)
- HCC 731.7K
- VKTX 4.9M
- Earning Date
- HCC 11-05-2025
- VKTX 10-22-2025
- Dividend Yield
- HCC 0.50%
- VKTX N/A
- EPS Growth
- HCC N/A
- VKTX N/A
- EPS
- HCC 0.77
- VKTX N/A
- Revenue
- HCC $1,221,350,000.00
- VKTX N/A
- Revenue This Year
- HCC N/A
- VKTX N/A
- Revenue Next Year
- HCC $42.35
- VKTX N/A
- P/E Ratio
- HCC $83.57
- VKTX N/A
- Revenue Growth
- HCC N/A
- VKTX N/A
- 52 Week Low
- HCC $38.00
- VKTX $18.92
- 52 Week High
- HCC $75.15
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- HCC 51.16
- VKTX 59.51
- Support Level
- HCC $61.87
- VKTX $30.86
- Resistance Level
- HCC $68.10
- VKTX $36.11
- Average True Range (ATR)
- HCC 2.59
- VKTX 2.08
- MACD
- HCC -0.49
- VKTX 0.05
- Stochastic Oscillator
- HCC 36.21
- VKTX 59.01
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.